Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

Bibliography

• Iyer SN, Wild JS, Schiedt MJ, Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995;125:779-85
   PubMed Web of Science ®Google Scholar
• Nagai S, Hamada K, Shigematsu M, Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002;41:1118-23
   PubMed Web of Science ®Google Scholar
• Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159:1061-9
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. Expert Opin Investig Drugs 2005;14:1443-7
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs 2006;15:823-8
   PubMed Web of Science ®Google Scholar
• Lasky J. Pirfenidone. IDrugs 2004;7:166-72
   PubMed Web of Science ®Google Scholar
• Schlondorff DO. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int 2008;74:860-6
   PubMed Web of Science ®Google Scholar
• Border WA, Okuda S, Languino LR, Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990;346:371-4
   PubMed Web of Science ®Google Scholar
• Border WA, Ruoslahti E. Transforming growth factor-beta 1 induces extracellular matrix formation in glomerulonephritis. Cell Differ Dev 1990;32:425-31
   PubMedGoogle Scholar
• Sharma K, Ziyadeh FN, Alzahabi B, Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997;46:854-9
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN. Role of transforming growth factor beta in diabetic nephropathy. Exp Nephrol 1994;2:137
   PubMedGoogle Scholar
• Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002;13:2600-10
   PubMed Web of Science ®Google Scholar
• Piek E, Moustakas A, Kurisaki A, TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999;112 (Pt 24):4557-68
   PubMed Web of Science ®Google Scholar
• Schiffer M, Schiffer LE, Gupta A, Inhibitory smads and tgf-Beta signaling in glomerular cells. J Am Soc Nephrol 2002;13:2657-66
   PubMed Web of Science ®Google Scholar
• Schnaper HW, Hayashida T, Poncelet AC. It's a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol 2002;13:1126-8
   PubMedGoogle Scholar
• Zavadil J, Bitzer M, Liang D, Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci USA 2001;98:6686-91
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;291:367-73
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289:211-8
   PubMed Web of Science ®Google Scholar
• Tada S, Nakamuta M, Enjoji M, Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 2001;28:522-7
   PubMed Web of Science ®Google Scholar
• Nakayama S, Mukae H, Sakamoto N, Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 2008;82:210-7
   PubMed Web of Science ®Google Scholar
• Hewitson TD, Kelynack KJ, Tait MG, Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 2001;14:453-60
   PubMed Web of Science ®Google Scholar
• Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000;24:477-91
   PubMed Web of Science ®Google Scholar
• Hale ML, Margolin SB, Krakauer T, Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun 2002;70:2989-94
   PubMed Web of Science ®Google Scholar
• Arumugam TV, Shiels IA, Margolin SB, Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine. Clin Exp Pharmacol Physiol 2002;29:996-1000
   PubMed Web of Science ®Google Scholar
• Nakazato H, Oku H, Yamane S, A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002;446:177-85
   PubMed Web of Science ®Google Scholar
• Nakanishi H, Kaibori M, Teshima S, Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes. J Hepatol 2004;41:730-6
   PubMed Web of Science ®Google Scholar
• Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000;204:119-26
   PubMed Web of Science ®Google Scholar
• Shi S, Wu J, Chen H, Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007;47:1268-76
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Ambrose PG, Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009;22:279-85
   PubMed Web of Science ®Google Scholar
• Taniyama M, Ohbayashi S, Narita M, Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol 1997;52:77-8
   PubMed Web of Science ®Google Scholar
• Babovic-Vuksanovic D, Widemann BC, Dombi E, Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol 2007;36:293-300
   PubMed Web of Science ®Google Scholar
• Shimizu T, Fukagawa M, Kuroda T, Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 1997;63:S239-43
   PubMed Web of Science ®Google Scholar
• Shimizu T, Kuroda T, Hata S, Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998;54:99-109
   PubMed Web of Science ®Google Scholar
• Park HS, Bao L, Kim YJ, Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse. J Korean Med Sci 2003;18:527-33
   PubMed Web of Science ®Google Scholar
• Miric G, Dallemagne C, Endre Z, Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001;133:687-94
   PubMed Web of Science ®Google Scholar
• RamachandraRao SP, Zhu Y, Ravasi T, Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009;20:1765-75
   PubMed Web of Science ®Google Scholar
• Leh S, Vaagnes O, Margolin SB, Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol Dial Transplant 2005;20:71-82
   PubMed Web of Science ®Google Scholar
• Duymelinck C, Deng JT, Dauwe SE, Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int 1998;54:804-18
   PubMed Web of Science ®Google Scholar
• Li B, Sehajpal PK, Khanna A, Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 1991;174:1259-62
   Google Scholar
• Wolf G, Thaiss F, Stahl RA. Cyclosporine stimulates expression of transforming growth factor-beta in renal cells. Possible mechanism of cyclosporine's antiproliferative effects. Transplantation 1995;60:237-41
   PubMed Web of Science ®Google Scholar
• Khanna A, Kapur S, Sharma V, In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation 1997;63:1037-9
   PubMed Web of Science ®Google Scholar
• Dosanjh A. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients. Eur J Pharmacol 2006;536:219-22
   PubMed Web of Science ®Google Scholar
• Dosanjh A. Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection. Transplant Proc 2007;39:2153-6
   PubMed Web of Science ®Google Scholar
• Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002;2:111-9
   PubMed Web of Science ®Google Scholar
• Brook NR, Waller JR, Bicknell GR, Nicholson ML. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J Surg Res 2005;125:137-43
   PubMed Web of Science ®Google Scholar
• Shihab FS, Bennett WM, Yi H, Andoh TF. Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 2005;79:419-26
   PubMed Web of Science ®Google Scholar
• Visner GA, Liu F, Bizargity P, Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation 2009;88:330-8
   PubMed Web of Science ®Google Scholar
• Cho ME, Smith DC, Branton MH, Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007;2:906-13
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7
   PubMed Web of Science ®Google Scholar
• Gahl WA, Brantly M, Troendle J, Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002;76:234-42
   PubMed Web of Science ®Google Scholar
• Walker JE, Giri SN, Margolin SB. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 2005;11:149-58
   PubMed Web of Science ®Google Scholar
• Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006;55:1663-5
   PubMed Web of Science ®Google Scholar
• Babovic-Vuksanovic D, Ballman K, Michels V, Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 2006;67:1860-2
   PubMed Web of Science ®Google Scholar
• Simone NL, Soule BP, Gerber L, Oral Pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiat Oncol 2007;2:19
   PubMed Web of Science ®Google Scholar
• Mesa RA, Tefferi A, Elliott MA, A phase II trial of pirfenidone (5-methyl-1-phenyl-2-1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 2001;114:111-3
   PubMed Web of Science ®Google Scholar
• Angulo P, MacCarty RL, Sylvestre PB, Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002;47:157-61
   PubMed Web of Science ®Google Scholar
• Bowen JD, Maravilla K, Margolin SB. Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Mult Scler 2003;9:280-3
   PubMed Web of Science ®Google Scholar